R. E. Marcus

2.5k total citations · 1 hit paper
47 papers, 1.9k citations indexed

About

R. E. Marcus is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, R. E. Marcus has authored 47 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 20 papers in Oncology and 12 papers in Genetics. Recurrent topics in R. E. Marcus's work include Hematopoietic Stem Cell Transplantation (13 papers), Acute Myeloid Leukemia Research (10 papers) and Lymphoma Diagnosis and Treatment (10 papers). R. E. Marcus is often cited by papers focused on Hematopoietic Stem Cell Transplantation (13 papers), Acute Myeloid Leukemia Research (10 papers) and Lymphoma Diagnosis and Treatment (10 papers). R. E. Marcus collaborates with scholars based in United Kingdom, Switzerland and United States. R. E. Marcus's co-authors include Peter Hoskin, KM Ardeshna, AJ Norton, B. W. Hancock, DC Linch, G. Vaughan Hudson, KA MacLennan, Peter Smith, A.M. Jelliffe and G. Bass and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

R. E. Marcus

45 papers receiving 1.8k citations

Hit Papers

CVP chemotherapy plus rituximab compared with CVP as firs... 2004 2026 2011 2018 2004 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    2004 714 citations R. E. Marcus Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. E. Marcus United Kingdom 18 1.1k 979 640 514 224 47 1.9k
J. O. Armitage United States 20 1.4k 1.3× 1.1k 1.1× 613 1.0× 588 1.1× 337 1.5× 54 2.5k
Patrizio Mazza Italy 22 1.1k 1.0× 680 0.7× 516 0.8× 478 0.9× 205 0.9× 98 1.8k
Hannes Wandt Germany 22 1.2k 1.1× 1.1k 1.1× 785 1.2× 1.0k 2.0× 149 0.7× 57 2.6k
Muhıt Özcan Türkiye 21 697 0.6× 944 1.0× 360 0.6× 673 1.3× 319 1.4× 174 2.0k
Daniel Espinouse France 19 584 0.5× 590 0.6× 356 0.6× 410 0.8× 181 0.8× 43 1.3k
Mathias Hänel Germany 21 814 0.7× 675 0.7× 484 0.8× 734 1.4× 75 0.3× 72 1.8k
Isabelle Moullet France 15 795 0.7× 720 0.7× 300 0.5× 376 0.7× 127 0.6× 22 1.5k
A. Z. S. Rohatiner United Kingdom 15 923 0.8× 575 0.6× 313 0.5× 309 0.6× 147 0.7× 41 1.4k
Ho‐Jin Shin South Korea 22 691 0.6× 655 0.7× 365 0.6× 944 1.8× 412 1.8× 182 2.0k
Fadhela Bouafia France 15 818 0.7× 668 0.7× 333 0.5× 331 0.6× 144 0.6× 24 1.5k

Countries citing papers authored by R. E. Marcus

Since Specialization
Citations

This map shows the geographic impact of R. E. Marcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. E. Marcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. E. Marcus more than expected).

Fields of papers citing papers by R. E. Marcus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. E. Marcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. E. Marcus. The network helps show where R. E. Marcus may publish in the future.

Co-authorship network of co-authors of R. E. Marcus

This figure shows the co-authorship network connecting the top 25 collaborators of R. E. Marcus. A scholar is included among the top collaborators of R. E. Marcus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. E. Marcus. R. E. Marcus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Magen, Hila, Shalev Fried, Orit Itzhaki, et al.. (2023). POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA. Hematological Oncology. 41(S2). 82–83. 1 indexed citations
2.
Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2017). Immunochemotherapy With Obinutuzumab Or Rituximab In Previously Untreated Follicular Lymphoma In The Randomized Phase III Gallium Study: Analysis By Chemotherapy Regimen. Haematologica. 1 indexed citations
3.
4.
Marcus, R. E.. (2006). Use of Rituximab in Patients with Follicular Lymphoma. Clinical Oncology. 19(1). 38–49. 7 indexed citations
5.
Schmitz, Norbert, Per Ljungman, Charlotte Cordonnier, et al.. (2004). Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplantation. 34(11). 955–962. 40 indexed citations
6.
Tauro, Sudhir, Gulnaz Begum, J Craig, et al.. (2003). Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. Bone Marrow Transplantation. 32(3). 273–278. 4 indexed citations
7.
Ardeshna, KM, Peter Smith, AJ Norton, et al.. (2003). Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. The Lancet. 362(9383). 516–522. 366 indexed citations
8.
9.
Visani, Giuseppe, D W Milligan, Fabiana Leoni, et al.. (2001). Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia. 15(5). 764–771. 25 indexed citations
10.
11.
Mahendra, P, Dave Johnson, M. Scott, et al.. (1996). High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.. PubMed. 17(6). 973–8. 9 indexed citations
12.
Farrington, M., et al.. (1996). Bacterial contamination of peripheral blood progenitor cells for transplantation. Transfusion Medicine. 6(2). 103–110. 33 indexed citations
13.
Mahendra, P, et al.. (1996). SEVERE HEMOSIDEROSIS POST ALLOGENEIC BONE MARROW TRANSPLANTATION. Hematological Oncology. 14(1). 33–35. 9 indexed citations
14.
Scott, M., et al.. (1995). Peripheral Blood Progenitor Cell Harvesting, in Multiple Myeloma and Malignant Lymphoma. Leukemia & lymphoma. 19(5-6). 479–484. 6 indexed citations
15.
Wimperis, J. Z., et al.. (1994). Autologous Bone Marrow Transplantation for Hodgkin's Disease-A Five-Year Single Centre Experience. Leukemia & lymphoma. 13(3-4). 263–272. 2 indexed citations
16.
Marcus, R. E., Alain Delmer, H. Zwierzina, et al.. (1994). A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.. PubMed. 8(1). 16–23. 40 indexed citations
17.
Nacheva, E, Martin J.S. Dyer, Peter Fischer, et al.. (1993). C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353). Blood. 82(1). 231–240. 30 indexed citations
18.
19.
Warren, R E, et al.. (1990). Prevention of infection by ciprofloxacin in neutropenia. Journal of Antimicrobial Chemotherapy. 26(suppl F). 109–123. 15 indexed citations
20.
Visani, Giuseppe, Alain Delmer, H. Zwierzina, et al.. (1989). Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.. PubMed. 4 Suppl 3. 36–7. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. O. Armitage Breakdown of academic impact, for papers by Patrizio Mazza Breakdown of academic impact, for papers by Hannes Wandt Breakdown of academic impact, for papers by Muhıt Özcan Breakdown of academic impact, for papers by Daniel Espinouse Breakdown of academic impact, for papers by Mathias Hänel Breakdown of academic impact, for papers by Isabelle Moullet Breakdown of academic impact, for papers by A. Z. S. Rohatiner Breakdown of academic impact, for papers by Ho‐Jin Shin Breakdown of academic impact, for papers by Fadhela Bouafia
Rankless by CCL
2026